GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Cash Flow for Lease Financing

GYRE (Gyre Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Cash Flow for Lease Financing?

Gyre Therapeutics's Cash Flow for Lease Financing for the three months ended in Jun. 2024 was $0.00 Mil. Gyre Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Mar. 2024 ), Gyre Therapeutics's Cash Flow for Lease Financing remained the same in Jun. 2024 ($0.00 Mil).

Gyre Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for Gyre Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Cash Flow for Lease Financing Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow for Lease Financing
- - -

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Cash Flow for Lease Financing Get a 7-Day Free Trial - - - - -

Gyre Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Cash Flow for Lease Financing
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.